1. Alactrita White paper (2019) https://www.alacrita.com/whitepapers/valuing-pharmaceutical-assets-when-to-use-npv-vs-rnpv. Accessed 18 May 2020
2. DiMasi JA et al (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33
3. Edison (2019) https://www.edisongroup.com/investment-themes/drug-pricing-market-access-and-reimbursement/23551/. Accessed 16 May 2020
4. Espacenet (2020) https://worldwide.espacenet.com/patent/. Accessed 18 May 2020
5. FDA Biosimilarity Guidance (2020) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-considerations-demonstrating-biosimilarity-therapeutic-protein-product-reference-product. Accessed 19 May 2020